Cargando…
Advances in stromal cell therapy for management of Alzheimer’s disease
Deposition of misfolded proteins and synaptic failure affects the brain in Alzheimer’s disease (AD). Its progression results in amnesia and cognitive impairment. Absence of treatment is due to excessive loss of neurons in the patients and the delayed effects of drugs. The enhanced pluripotency, prol...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576849/ https://www.ncbi.nlm.nih.gov/pubmed/36267273 http://dx.doi.org/10.3389/fphar.2022.955401 |
_version_ | 1784811620880351232 |
---|---|
author | Srivastava, Rashi Li, Aidong Datta, Tirtharaj Jha, Niraj Kumar Talukder, Salehikram Jha, Saurabh Kumar Chen, Zhe-Sheng |
author_facet | Srivastava, Rashi Li, Aidong Datta, Tirtharaj Jha, Niraj Kumar Talukder, Salehikram Jha, Saurabh Kumar Chen, Zhe-Sheng |
author_sort | Srivastava, Rashi |
collection | PubMed |
description | Deposition of misfolded proteins and synaptic failure affects the brain in Alzheimer’s disease (AD). Its progression results in amnesia and cognitive impairment. Absence of treatment is due to excessive loss of neurons in the patients and the delayed effects of drugs. The enhanced pluripotency, proliferation, differentiation, and recombination characteristics of stromal cells into nerve cells and glial cells present them as a potential treatment for AD. Successful evidence of action in animal models along with positive results in preclinical studies further encourage its utilization for AD treatment. With regard to humans, cell replacement therapy involving mesenchymal stromal cells, induced-pluripotent stromal cells, human embryonic stromal cells, and neural stems show promising results in clinical trials. However, further research is required prior to its use as stromal cell therapy in AD related disorders. The current review deals with the mechanism of development of anomalies such as Alzheimer’s and the prospective applications of stromal cells for treatment. |
format | Online Article Text |
id | pubmed-9576849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95768492022-10-19 Advances in stromal cell therapy for management of Alzheimer’s disease Srivastava, Rashi Li, Aidong Datta, Tirtharaj Jha, Niraj Kumar Talukder, Salehikram Jha, Saurabh Kumar Chen, Zhe-Sheng Front Pharmacol Pharmacology Deposition of misfolded proteins and synaptic failure affects the brain in Alzheimer’s disease (AD). Its progression results in amnesia and cognitive impairment. Absence of treatment is due to excessive loss of neurons in the patients and the delayed effects of drugs. The enhanced pluripotency, proliferation, differentiation, and recombination characteristics of stromal cells into nerve cells and glial cells present them as a potential treatment for AD. Successful evidence of action in animal models along with positive results in preclinical studies further encourage its utilization for AD treatment. With regard to humans, cell replacement therapy involving mesenchymal stromal cells, induced-pluripotent stromal cells, human embryonic stromal cells, and neural stems show promising results in clinical trials. However, further research is required prior to its use as stromal cell therapy in AD related disorders. The current review deals with the mechanism of development of anomalies such as Alzheimer’s and the prospective applications of stromal cells for treatment. Frontiers Media S.A. 2022-10-04 /pmc/articles/PMC9576849/ /pubmed/36267273 http://dx.doi.org/10.3389/fphar.2022.955401 Text en Copyright © 2022 Srivastava, Li, Datta, Jha, Talukder, Jha and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Srivastava, Rashi Li, Aidong Datta, Tirtharaj Jha, Niraj Kumar Talukder, Salehikram Jha, Saurabh Kumar Chen, Zhe-Sheng Advances in stromal cell therapy for management of Alzheimer’s disease |
title | Advances in stromal cell therapy for management of Alzheimer’s disease |
title_full | Advances in stromal cell therapy for management of Alzheimer’s disease |
title_fullStr | Advances in stromal cell therapy for management of Alzheimer’s disease |
title_full_unstemmed | Advances in stromal cell therapy for management of Alzheimer’s disease |
title_short | Advances in stromal cell therapy for management of Alzheimer’s disease |
title_sort | advances in stromal cell therapy for management of alzheimer’s disease |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576849/ https://www.ncbi.nlm.nih.gov/pubmed/36267273 http://dx.doi.org/10.3389/fphar.2022.955401 |
work_keys_str_mv | AT srivastavarashi advancesinstromalcelltherapyformanagementofalzheimersdisease AT liaidong advancesinstromalcelltherapyformanagementofalzheimersdisease AT dattatirtharaj advancesinstromalcelltherapyformanagementofalzheimersdisease AT jhanirajkumar advancesinstromalcelltherapyformanagementofalzheimersdisease AT talukdersalehikram advancesinstromalcelltherapyformanagementofalzheimersdisease AT jhasaurabhkumar advancesinstromalcelltherapyformanagementofalzheimersdisease AT chenzhesheng advancesinstromalcelltherapyformanagementofalzheimersdisease |